Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Medicare Rx Benefit Could Lead To Tightened Pediatric Exclusivity - CVS CEO

  • News

Executive Summary

Congress will likely tighten the pediatric exclusivity incentive as it considers a Medicare drug benefit, CVS CEO Tom Ryan predicted during an earnings call.

You may also be interested in...



CVS Sees Opportunity To Increase Market Share Under Medicare Rx Benefit

CVS expects to benefit disproportionately under a Medicare prescription drug program, CEO Tom Ryan told an Oct. 30 earnings conference call.

Merck Fosamax Distribution Deal With CVS ProCare Draws Protest From NCPA

The National Community Pharmacists Association is questioning the clinical necessity of limiting distribution of the 40 mg dose of Merck's Fosamax for Paget's disease to CVS ProCare.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

See All
UsernamePublicRestriction

Register

PS037328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By